Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Development Officer | February 05, 2021 | March 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date February 05, 2021 · Filed March 29, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.43 · Expires 2031-02-08 | Direct | 3,504 |
Reported balance
After 2021-02-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-02-08 · Grant · Acquired 3,504 · Balance 3,504 F1: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 532 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · derivative · entry 6 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 532 Underlying: Common Stock · 532 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 3,188 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · derivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,188 Underlying: Common Stock · 3,188 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,623 | $116.79 | $189,550.49 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · nonDerivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,651 F7 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,395 | $116.78 | $162,912.29 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,189 F5 · kind: Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.90 to $117.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 824 | $116.85 | $96,285.80 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,934 F3 · kind: Sale of 824 shares of common stock issued upon vesting of 2,430 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,606) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:12 UTC Amendment | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 3,504 | $0.00 Strike: $117.43 | $0.00 |
DisclosureSEC source: 0001209191-21-023372 · doc4a.xml · derivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,504 Underlying: Common Stock · 3,504 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 704 | $113.79 | $80,108.51 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,328 F1 · kind: Sale of 704 shares of common stock issued upon vesting of 1,338 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (634) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.66 to $116.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $90.74 | $204,806.50 |
DisclosureSEC source: 0001209191-20-058539 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,694 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $118.89 | $268,324.35 |
DisclosureSEC source: 0001209191-20-045742 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,663 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.34 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 18,057 | $0.00 Strike: $81.05 | $0.00 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · derivative · entry 12 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,383 Underlying: Common Stock · 18,057 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Option granted February 07, 2019 and vests monthly over four years. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,833 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · derivative · entry 11 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,340 Underlying: Common Stock · 15,833 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option granted February 05, 2018 and vests monthly over four years. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 18,571 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · derivative · entry 10 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,289 Underlying: Common Stock · 18,571 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 06, 2017 and vests monthly over four years. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 9,094 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · derivative · entry 9 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,094 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 05, 2016 and vested monthly over four years. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 18,057 | $114.94 | $2,075,549.23 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 8 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 18,057 | $81.05 | $1,463,519.85 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 7 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,833 | $114.94 | $1,819,913.10 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 6 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,833 | $81.49 | $1,290,231.17 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 18,571 | $114.94 | $2,134,630.60 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 18,571 | $43.24 | $803,010.04 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 9,094 | $114.94 | $1,045,303.46 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 9,094 | $35.99 | $327,293.06 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,934 | $99.46 | $192,351.19 |
DisclosureSEC source: 0001209191-20-026064 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.65 to $101.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 251 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,623 | $103.33 | $167,701.67 |
DisclosureSEC source: 0001209191-20-008484 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,641 F1 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,084 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,461) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.23 to $104.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 2,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · derivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,430 Underlying: Common Stock · 2,430 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F10 · derivative.exercise_date: The Restricted Stock Units vests in full on February 6, 2021. F10 · derivative.expiration_date: The Restricted Stock Units vests in full on February 6, 2021. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 15,337 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · derivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,337 Underlying: Common Stock · 15,337 shares Expires 2030-02-06 F8 · derivative.exercise_date: Represents option which vests in full on February 6, 2021. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,395 | $101.56 | $141,670.06 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,180 F6 · kind: Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 704 | $103.06 | $72,555.86 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,925 F4 · kind: Sale of 704 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (633) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $104.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,342 | $103.00 | $138,223.05 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,292 F1 · kind: Sale of 1,342 shares of common stock issued upon vesting of 2,550 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,208) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.85 to $105.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 108 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on August 30, 2019. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 25,600 | $43.24 Strike: $43.24 | $1,106,944.00 |
DisclosureSEC source: 0001209191-19-043914 · doc4.xml · derivative · entry 6 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,860 Underlying: Common Stock · 25,600 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option granted February 6, 2017 and vests monthly over four years. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 18,756 | $32.99 Strike: $32.99 | $618,760.44 |
DisclosureSEC source: 0001209191-19-043914 · doc4.xml · derivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,756 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 25,600 | $93.52 | $2,394,227.20 |
DisclosureSEC source: 0001209191-19-043914 · doc4.xml · nonDerivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,976 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.77 to $94.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 25,600 | $43.24 | $1,106,944.00 |
DisclosureSEC source: 0001209191-19-043914 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 18,756 | $91.74 | $1,720,630.43 |
DisclosureSEC source: 0001209191-19-043914 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,976 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.66 to $91.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:11 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 18,756 | $32.99 | $618,760.44 |
DisclosureSEC source: 0001209191-19-043914 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 30,680 | $32.99 Strike: $32.99 | $1,012,133.20 |
DisclosureSEC source: 0001209191-19-042522 · doc4.xml · derivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,756 Underlying: Common Stock · 30,680 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 30,680 | $87.50 | $2,684,506.14 |
DisclosureSEC source: 0001209191-19-042522 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,976 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $86.08 to $88.38. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 30,680 | $32.99 | $1,012,133.20 |
DisclosureSEC source: 0001209191-19-042522 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 100 | $32.99 Strike: $32.99 | $3,299.00 |
DisclosureSEC source: 0001209191-19-041925 · doc4.xml · derivative · entry 6 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,436 Underlying: Common Stock · 100 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 100 | $87.59 | $8,759.00 |
DisclosureSEC source: 0001209191-19-041925 · doc4.xml · nonDerivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,976 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 100 | $32.99 | $3,299.00 |
DisclosureSEC source: 0001209191-19-041925 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 7,120 | $32.99 Strike: $32.99 | $234,888.80 |
DisclosureSEC source: 0001209191-19-041925 · doc4.xml · derivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,536 Underlying: Common Stock · 7,120 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 7,120 | $87.63 | $623,957.64 |
DisclosureSEC source: 0001209191-19-041925 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,976 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.50 to $87.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 7,120 | $32.99 | $234,888.80 |
DisclosureSEC source: 0001209191-19-041925 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 21:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 2,100 | $32.99 Strike: $32.99 | $69,279.00 |
DisclosureSEC source: 0001209191-19-038288 · doc4.xml · derivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,656 Underlying: Common Stock · 2,100 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 21:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,100 | $87.82 | $184,416.54 |
DisclosureSEC source: 0001209191-19-038288 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,976 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.53 to $87.965. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 21:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,100 | $32.99 | $69,279.00 |
DisclosureSEC source: 0001209191-19-038288 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,432 | $32.99 Strike: $32.99 | $47,241.68 |
DisclosureSEC source: 0001209191-19-037472 · doc4.xml · derivative · entry 6 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,756 Underlying: Common Stock · 1,432 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,836 | $19.59 Strike: $19.59 | $310,227.24 |
DisclosureSEC source: 0001209191-19-037472 · doc4.xml · derivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,836 shares Expires 2024-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted January 16, 2014 and vested monthly over four years. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,432 | $83.29 | $119,270.99 |
DisclosureSEC source: 0001209191-19-037472 · doc4.xml · nonDerivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,976 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $83.18 to $83.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,432 | $32.99 | $47,241.68 |
DisclosureSEC source: 0001209191-19-037472 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.